Additional file 2: of A gel-based PCR method to differentiate sheeppox virus field isolates from vaccine strains

Figure S1. Gel picture of PCR products for the remaining capripoxvirus samples. These sample were tested in this study, but not presented in Fig. 2 of the manuscript. The PCR products of 218 bp, 302 bp and 338 bp represent SPPV vaccine strains, SPPV field isolates/GTPVs, and LSDVs respectively. First row: MM = 50 bp DNA ladder; a = positive control plasmid of the SPPV field isolates; b = positive control plasmid of the SPPV vaccine strain; c = Negative control; Lane 5 to 15 (sample 23 to 33 in Table 1 of the manuscript). Second row: MM = 50 bp; Lane 2 to 14 (sample 34 to 46 in Table 1 of the manuscript). (PDF 104 kb

Additional file 3: of A gel-based PCR method to differentiate sheeppox virus field isolates from vaccine strains

Figure S2. Determination of the limits of detection of the PCR assay. Defined amount for the plasmid genotype standard (104, 103, 100, 80, 60, 40, 20, 10, 1 and 0) for SPPV vaccine (A) and SPPV field isolates (B) were tested in parallel reactions and run on agarose gel. (PDF 77 kb

Additional file 4: of A gel-based PCR method to differentiate sheeppox virus field isolates from vaccine strains

Figure S3. Gel picture of PCR for the non-capripoxvirus samples tested in this study. MM = 50 bp DNA ladder; a = positive control plasmid of the SPPV field isolates; b = positive control plasmid of the SPPV vaccine strain; c = Negative control; 1–5 (ORF viruses); 6 (BPSV); 7–8 (Mccp); 9 (cDNA, PPRV); 10 (BOHV-1); 11 (BOHV-2). (PDF 45 kb

Additional file 1: of A gel-based PCR method to differentiate sheeppox virus field isolates from vaccine strains

Table S1. Non-capripoxvirus samples tested for specificity study. (DOCX 16 kb